Evaluating a new nanotherapy for Huntington's disease
Pre-Clinical Evaluation of a Rationally Designed Nanotherapeutic for Huntington's Disease
This study is testing a new treatment that uses tiny gold particles to deliver a medicine aimed at protecting brain cells in people with Huntington's disease, helping to reduce damage while keeping normal brain communication intact.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neurano Bioscience NIH-funded |
| Lab location | 1 site (La Jolla, UNITED STATES) |
| Project ID | NIH-10258489 on NIH RePORTER |
What this research studies
This research focuses on developing a novel nanotherapeutic designed to target and inhibit extrasynaptic NMDA receptors, which are implicated in the neurodegenerative processes of Huntington's disease. By attaching memantine, a known NMDA receptor antagonist, to a gold nanoparticle, the therapy aims to provide neuroprotection without affecting normal synaptic communication. The approach has shown promising results in preclinical models, suggesting it could effectively mitigate neuronal damage associated with Huntington's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Huntington's disease who are experiencing cognitive and psychiatric symptoms.
Not a fit: Patients with other neurodegenerative disorders not related to Huntington's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that protects neurons from damage in Huntington's disease, potentially improving patient outcomes.
How similar studies have performed: Preliminary studies have shown success with similar approaches, indicating potential for this novel therapy to provide significant neuroprotection.
Where this research is happening
La Jolla, UNITED STATES
- Neurano Bioscience — La Jolla, United States (Active)
Researchers
- Principal investigator: Molokanova, Elena — Neurano Bioscience
- Study coordinator: Molokanova, Elena
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.